A detailed history of Morgan Stanley transactions in Bio Atla, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,910,144 shares of BCAB stock, worth $2.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,910,144
Previous 1,913,115 0.16%
Holding current value
$2.92 Million
Previous $4.71 Million 39.61%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.88 - $3.46 $5,585 - $10,279
-2,971 Reduced 0.16%
1,910,144 $6.57 Million
Q4 2023

Feb 13, 2024

BUY
$1.27 - $3.18 $396,655 - $993,199
312,327 Added 19.51%
1,913,115 $4.71 Million
Q3 2023

Nov 15, 2023

SELL
$1.7 - $3.07 $154,871 - $279,680
-91,101 Reduced 5.38%
1,600,788 $2.72 Million
Q2 2023

Aug 14, 2023

SELL
$2.83 - $3.87 $528,168 - $722,265
-186,632 Reduced 9.94%
1,691,889 $5.08 Million
Q1 2023

May 15, 2023

BUY
$2.3 - $8.25 $131,461 - $471,545
57,157 Added 3.14%
1,878,521 $5.03 Million
Q4 2022

Feb 14, 2023

BUY
$7.63 - $11.01 $1.32 Million - $1.91 Million
173,600 Added 10.54%
1,821,364 $15 Million
Q3 2022

Nov 14, 2022

BUY
$2.94 - $11.87 $1.67 Million - $6.75 Million
568,986 Added 52.74%
1,647,764 $12.7 Million
Q2 2022

Oct 27, 2022

SELL
$2.13 - $5.38 $1.1 Million - $2.77 Million
-515,213 Reduced 32.32%
1,078,778 $3.08 Million
Q2 2022

Aug 15, 2022

SELL
$2.13 - $5.38 $1.1 Million - $2.77 Million
-515,213 Reduced 32.32%
1,078,778 $3.08 Million
Q1 2022

Oct 27, 2022

BUY
$4.38 - $18.78 $2.26 Million - $9.68 Million
515,213 Added 47.76%
1,593,991 $7.97 Million
Q1 2022

May 13, 2022

BUY
$4.38 - $18.78 $4.09 Million - $17.5 Million
933,752 Added 141.43%
1,593,991 $7.97 Million
Q4 2021

Feb 14, 2022

BUY
$19.0 - $30.95 $8.1 Million - $13.2 Million
426,454 Added 182.41%
660,239 $13 Million
Q3 2021

Nov 15, 2021

BUY
$29.44 - $43.74 $6.88 Million - $10.2 Million
233,785 New
233,785 $6.88 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $55.5M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.